September 17, 2024 08:16 PM EDTUpdated 06:27 AM
People
Health Tech

All of 23and­Me's in­de­pen­dent board mem­bers re­sign over dis­agree­ments with CEO

Kyle LaHucik

Senior Reporter

All sev­en in­de­pen­dent di­rec­tors of 23andMe’s board have im­me­di­ate­ly re­signed, they wrote in a pub­lic let­ter Tues­day, ex­press­ing con­cerns over their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times